Data from the INHALE-1 trial presented at the American Diabetes Association Scientific Sessions indicates that MannKind’s Technosphere insulin (Afrezza) is a safe and effective alternative to injected rapid-acting analogs for children and adolescents with diabetes. The study found that the inhaled formulation achieved similar HbA1c reductions to standard care while resulting in less weight gain and higher patient satisfaction scores.